Joseph Catanzaro
Stock Analyst at Mizuho Securities
(4.59)
# 930
Out of 4,596 analysts
416
Total ratings
45%
Success rate
12.4%
Average return
Main Sectors:
Stocks Rated by Joseph Catanzaro
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TNGX Tango Therapeutics | Maintained: Buy | $36 → $40 | $27.18 | +47.17% | 9 | Jul 17, 2026 | |
| KYMR Kymera Therapeutics | Maintained: Buy | $140 | $103.40 | +35.40% | 3 | Jul 16, 2026 | |
| SYRE Spyre Therapeutics | Maintained: Buy | $84 → $120 | $98.33 | +22.04% | 4 | Jul 13, 2026 | |
| QTTB Q32 Bio | Reiterated: Buy | $14 → $36 | $15.68 | +129.59% | 2 | Jul 13, 2026 | |
| NRIX Nurix Therapeutics | Maintained: Buy | $30 → $34 | $23.21 | +46.49% | 27 | Jul 13, 2026 | |
| RVMD Revolution Medicines | Maintained: Buy | $185 → $215 | $187.53 | +14.65% | 16 | Jul 6, 2026 | |
| APGE Apogee Therapeutics | Downgraded: Hold | $110 → $135 | $134.09 | +0.68% | 9 | Jun 24, 2026 | |
| AVTX Avalo Therapeutics | Maintained: Buy | $39 → $45 | $18.25 | +146.58% | 3 | May 14, 2026 | |
| UPB Upstream Bio | Maintained: Buy | $51 → $50 | $6.31 | +692.39% | 2 | May 14, 2026 | |
| ERAS Erasca | Maintained: Buy | $28 → $26 | $18.15 | +43.25% | 4 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $50 | $24.17 | +106.87% | 1 | Apr 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $18 | $11.90 | +51.26% | 1 | Apr 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $26 | $9.21 | +182.30% | 1 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $48 | $38.06 | +26.12% | 3 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $18 | $27.10 | -33.58% | 1 | Dec 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $4.5 | $0.5994 | n/a | 6 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $36 → $38 | $5.30 | n/a | 5 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $3.25 | $3.10 | n/a | 15 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $53 | $82.54 | n/a | 27 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $4.75 → $4.25 | $7.17 | n/a | 15 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 | $0.8554 | n/a | 16 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $7.5 → $6 | $4.07 | n/a | 37 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $50 → $45 | $15.14 | n/a | 5 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $37 → $38 | $53.03 | n/a | 11 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $105 → $110 | $130.21 | n/a | 20 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $15 → $3 | $0.5906 | n/a | 15 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $40 → $15 | $10.07 | n/a | 25 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $19 | $8.66 | n/a | 2 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 → $19 | $1.17 | n/a | 17 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $15 | $1.69 | n/a | 10 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 → $8 | $1.60 | n/a | 9 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $30 | $1.50 | n/a | 8 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $5 → $1.75 | $3.85 | n/a | 9 | Aug 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $20 | $2.50 | n/a | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $15 | $8.17 | n/a | 39 | Apr 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $15 → $1.75 | $1.44 | n/a | 8 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $1.5 → $1.75 | $2.02 | n/a | 4 | Sep 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $6 | $32.89 | n/a | 4 | May 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $15 | $1.13 | n/a | 3 | May 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 → $4 | $27.24 | n/a | 4 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $45 → $36 | $10.70 | n/a | 4 | Mar 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $15 → $17 | $1.32 | n/a | 7 | Aug 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $28 → $18 | $2.23 | n/a | 4 | Apr 7, 2020 |
Tango Therapeutics
Jul 17, 2026
Maintained: Buy
Price Target: $36 → $40
Current: $27.18
Upside: +47.17%
Kymera Therapeutics
Jul 16, 2026
Maintained: Buy
Price Target: $140
Current: $103.40
Upside: +35.40%
Spyre Therapeutics
Jul 13, 2026
Maintained: Buy
Price Target: $84 → $120
Current: $98.33
Upside: +22.04%
Q32 Bio
Jul 13, 2026
Reiterated: Buy
Price Target: $14 → $36
Current: $15.68
Upside: +129.59%
Nurix Therapeutics
Jul 13, 2026
Maintained: Buy
Price Target: $30 → $34
Current: $23.21
Upside: +46.49%
Revolution Medicines
Jul 6, 2026
Maintained: Buy
Price Target: $185 → $215
Current: $187.53
Upside: +14.65%
Apogee Therapeutics
Jun 24, 2026
Downgraded: Hold
Price Target: $110 → $135
Current: $134.09
Upside: +0.68%
Avalo Therapeutics
May 14, 2026
Maintained: Buy
Price Target: $39 → $45
Current: $18.25
Upside: +146.58%
Upstream Bio
May 14, 2026
Maintained: Buy
Price Target: $51 → $50
Current: $6.31
Upside: +692.39%
Erasca
May 12, 2026
Maintained: Buy
Price Target: $28 → $26
Current: $18.15
Upside: +43.25%
Apr 30, 2026
Initiated Coverage: Buy
Price Target: $50
Current: $24.17
Upside: +106.87%
Apr 15, 2026
Initiated Coverage: Buy
Price Target: $18
Current: $11.90
Upside: +51.26%
Mar 2, 2026
Initiated Coverage: Buy
Price Target: $26
Current: $9.21
Upside: +182.30%
Jan 9, 2026
Reiterated: Buy
Price Target: $48
Current: $38.06
Upside: +26.12%
Dec 18, 2025
Initiated Coverage: Hold
Price Target: $18
Current: $27.10
Upside: -33.58%
Mar 21, 2025
Maintained: Buy
Price Target: $4.5
Current: $0.5994
Upside: n/a
Mar 20, 2025
Maintained: Buy
Price Target: $36 → $38
Current: $5.30
Upside: n/a
Mar 7, 2025
Maintained: Buy
Price Target: $3.25
Current: $3.10
Upside: n/a
Mar 6, 2025
Maintained: Hold
Price Target: $53
Current: $82.54
Upside: n/a
Mar 3, 2025
Maintained: Hold
Price Target: $4.75 → $4.25
Current: $7.17
Upside: n/a
Feb 28, 2025
Maintained: Buy
Price Target: $10
Current: $0.8554
Upside: n/a
Feb 28, 2025
Maintained: Hold
Price Target: $7.5 → $6
Current: $4.07
Upside: n/a
Feb 27, 2025
Maintained: Buy
Price Target: $50 → $45
Current: $15.14
Upside: n/a
Feb 12, 2025
Maintained: Buy
Price Target: $37 → $38
Current: $53.03
Upside: n/a
Feb 12, 2025
Maintained: Buy
Price Target: $105 → $110
Current: $130.21
Upside: n/a
Jan 29, 2025
Rated: Buy
Price Target: $15 → $3
Current: $0.5906
Upside: n/a
Jan 17, 2025
Maintained: Buy
Price Target: $40 → $15
Current: $10.07
Upside: n/a
Nov 6, 2024
Rated: Buy
Price Target: $19
Current: $8.66
Upside: n/a
Oct 31, 2024
Maintained: Buy
Price Target: $10 → $19
Current: $1.17
Upside: n/a
Oct 8, 2024
Rated: Buy
Price Target: $15
Current: $1.69
Upside: n/a
Sep 16, 2024
Reiterated: Buy
Price Target: $10 → $8
Current: $1.60
Upside: n/a
Sep 16, 2024
Rated: Buy
Price Target: $30
Current: $1.50
Upside: n/a
Aug 27, 2024
Downgraded: Hold
Price Target: $5 → $1.75
Current: $3.85
Upside: n/a
Apr 22, 2024
Initiated Coverage: Buy
Price Target: $20
Current: $2.50
Upside: n/a
Apr 8, 2024
Maintained: Buy
Price Target: $15
Current: $8.17
Upside: n/a
May 23, 2023
Downgraded: Hold
Price Target: $15 → $1.75
Current: $1.44
Upside: n/a
Sep 14, 2022
Maintained: Hold
Price Target: $1.5 → $1.75
Current: $2.02
Upside: n/a
May 31, 2022
Maintained: Buy
Price Target: $6
Current: $32.89
Upside: n/a
May 31, 2022
Maintained: Buy
Price Target: $15
Current: $1.13
Upside: n/a
May 12, 2022
Maintained: Buy
Price Target: $10 → $4
Current: $27.24
Upside: n/a
Mar 9, 2022
Maintained: Buy
Price Target: $45 → $36
Current: $10.70
Upside: n/a
Aug 21, 2020
Maintained: Buy
Price Target: $15 → $17
Current: $1.32
Upside: n/a
Apr 7, 2020
Maintained: Buy
Price Target: $28 → $18
Current: $2.23
Upside: n/a